PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy

BACKGROUND. Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive netwo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: Kalathil, Suresh Gopi, Lugade, Amit Anand, Miller, Austin, Iyer, Renuka, Thanavala, Yasmin
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2016
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986927/
https://ncbi.nlm.nih.gov/pubmed/27540594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86182
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares